|
Clinical Services (Leukemia Program):
|
|
Research
|
|
The Dana-Farber Cancer Institute ALL Consortium, headed by physicians at Children's Hospital Boston and the Dana-Farber Cancer Institute is an international leader in ALL treatment and research, including:
|
|
- Treatment protocol design and outcome
- Identifying and reducing the risk of neuropsychologic late effects in survivors of childhood ALL
- Identifying and reducing the risk of cardiac dysfunction in survivors of childhood ALL
- Identifying and reducing the risk of side effects from chemotherapeutic agents used to treat ALL, including asparaginase and corticosteroids
- Ongoing assessment of patients' quality-of-life during after therapy
- Using state-of-the-art laboratory technology to characterize novel chromosomal and molecular abnormalities in order to identify biologically distinctive subsets of ALL that may require different therapy
- Investigating the role of the body's immune system and the tumor-associated angiogenesis in the development and treatment of ALL, with the goal of developing novel therapies
|
|
Investigational therapies for refractory or relapsed disease, including:
|
|
|
- Trials of tumor vaccines uniquely available at Children's Hospital Boston/Dana-Farber Cancer Institute
- Investigational drugs available via the Children's Oncology Group
|
|
In addition, members of the Leukemia Program are active member of the Children's Oncology Group research program evaluating best primary therapy for patients with newly diagnosed disease:
|
|
|
- Children's Oncology Group studies for treatment of patients with relapsed disease
- Alternative donor stem cell transplantation for relapsed disease
|
|
|
|
